About: Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
Creator	Monie, Archana Huang, Bruce Wang, Mei-Cheng Wu, Chao-Yi Wu, T.-C Chien-Fu, & Tseng, Chih-Wen
Source	Medline; PMC
abstract	There is an urgent need to develop new innovative therapies for the control of cancer. Antigen-specific immunotherapy and the employment of proteasome inhibitors have emerged as two potentially plausible approaches for the control of cancer. In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 E7 antigen (CRT/E7) with the proteasome inhibitor, bortezomib, for their ability to generate E7-specific immune responses and antitumor effects in vaccinated mice. We found that the combination of treatment with bortezomib and CRT/E7(detox) DNA generated more potent E7-specific CD8+ T cell immune responses and better therapeutic effects against TC-1 tumors in tumor-bearing mice compared to monotherapy. Furthermore, we found that treatment with bortezomib led to increased apoptosis of TC-1 tumor cells and could render the TC-1 tumor cells more susceptible to lysis by E7-specific CD8+ T cells. Our data have significant implications for future clinical translation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00109-008-0370-y) contains supplementary material, which is available to authorized users.
has issue date	2008-06-10(xsd:dateTime)
bibo:doi	10.1007/s00109-008-0370-y
bibo:pmid	18542898
has license	no-cc
sha1sum (hex)	1ecbabb9d0605dcfa2504148930aa1b7322cea27
schema:url	https://doi.org/10.1007/s00109-008-0370-y
resource representing a document's title	Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
has PubMed Central identifier	PMC2535907
has PubMed identifier	18542898
schema:publication	J Mol Med (Berl)
resource representing a document's body	covid:1ecbabb9d0605dcfa2504148930aa1b7322cea27#body_text
is schema:about of	named entity 'MEDIATED' named entity 'immunotherapy' named entity 'tumors' named entity 'type 16' named entity 'linked' named entity 'effects' named entity 'specific' named entity 'bortezomib' named entity 'DNA VACCINATION' named entity 'TREATMENT' named entity 'IMMUNITY' named entity 'TC-1' named entity 'CRT' named entity 'BEARING' named entity 'HAVE' named entity 'LED' named entity 'DNA VACCINE' named entity 'SUSCEPTIBLE' named entity 'INCREASED APOPTOSIS' named entity 'NEED' named entity 'HUMAN PAPILLOMAVIRUS TYPE 16' named entity 'DNA' named entity 'ANTITUMOR' named entity 'EFFECTS' named entity 'APPROACHES' named entity 'COMPARED' named entity 'THEIR' named entity 'GENERATED' named entity 'FUTURE' named entity 'TUMORS' named entity 'PROTEASOME INHIBITORS' named entity 'MICE' named entity 'IMMUNOTHERAPY' named entity 'CLINICAL' named entity 'RENDER' named entity 'BORTEZOMIB' named entity 'ANTITUMOR' named entity 'OUR' named entity 'PROTEASOME INHIBITOR' named entity 'SIGNIFICANT' named entity 'BETTER' named entity 'ANTIGEN' named entity 'BORTEZOMIB' named entity 'INDUCED' named entity 'CD8' named entity 'T-CELL' named entity 'TUMOR CELLS' named entity 'CANCER' named entity 'T CELL' named entity 'T CELLS' named entity 'VACCINATED' named entity 'FOUND' named entity 'GENERATE' named entity 'IMMUNE RESPONSES' named entity 'LYSIS' named entity 'CURRENT' named entity 'THERAPIES' named entity 'PROTEASOME INHIBITOR' named entity 'TRANSLATION' named entity 'TREATMENT' named entity 'SPECIFIC' named entity 'EMPLOYMENT' named entity 'SPECIFIC' named entity 'NEW' named entity 'ANTIGEN' named entity 'TUMOR' named entity 'DATA' named entity 'URGENT' named entity 'CD8' named entity 'STUDY' named entity 'THERAPEUTIC' named entity 'ENCODING' named entity 'MONOTHERAPY' named entity 'CALRETICULIN' named entity 'COMBINATION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software